Abstract
Introduction
Vaccination is one of medical science's greatest achievements; it has led to the eradication of several infectious diseases and to a reduction in morbidity and mortality from many others [ 1 ] . The majority of licensed vaccines consist of live, live-attenuated , or inactivated pathogens that were developed by empirical approaches [ 2 ] . Understanding vaccine-mediated correlates of immunity is critical for rational design of novel pathogen-free vaccines against infectious diseases for which no effective vaccine currently exists, or to improve the safety and/or effi cacy of existing vaccines [ 2 -6 ] .
It is generally thought that the most effective vaccines confer protection via mediation of neutralizing antibodies , which are readily detectable by in vitro assays. Hence, most effort continues to be invested in designing vaccines that induce antibody-mediated protective immunity [ 6 , 7 ] . In recent years, however, the focus on developing T cell-targeted vaccines has increased, as it has become clear that successful vaccination relies on both antibody-and T cell-mediated immunity (reviewed in Ref. [ 3 , 8 ] ).
The indispensable role of cellular immunity was observed even prior to modern advances in microbiology and immunology, from the historically recorded cases known as "experiments of nature." As early as the nineteenth century, Jenner and colleagues observed that a smallpox -immune mother had brought forth an infant who died a few days after birth owing to an infection contracted in utero, as the baby was born with pocks/pustules [ 9 , 10 ] . Given that the mother's antibody repertoire circulates within the fetus and babies are born with underdeveloped cellular immunity [ 11 -13 ] , we can now surmise that protection from smallpox requires cellular immunity. Another example of the critical role of cellular immunity includes a case report for progressive vaccinia virus (VACV) infection in a subject with normal anti-viral antibody responses [ 14 ] .
Immune CD8 + T cells recognize infected cells via short microbial peptide epitopes presented by the host's major histocompatibility complex (MHC)-encoded class I molecules. Of note, MHC class I molecules present cytoplasmic antigens because their assembly with peptides predominantly occurs within the endoplasmic reticulum, though under infl ammatory conditions it can occur within vacuoles as well (reviewed in Refs. [ 15 , 16 ] ). Recent studies have shown that CD8 + T cells play a critical role in conferring protective immunity against a variety of infectious diseases, including those caused by respiratory viruses [ 17 -21 ] , poxviruses [ 22 ] , cytomegalovirus [ 23 ] , human immunodefi ciency virus (HIV; [ 24 ] ), Plasmodium species [ 25 , 26 ] , and M. tuberculosis [ 27 ] . Hence, T cell epitope-based vaccines can complement current efforts in developing safe and effective antibody-targeted subunit vaccines .
The challenge impeding the development of T cell -targeted subunit vaccines is identifying which of the microbe's peptide epitopes confer protective immunity amongst the many that are presented [ 28 ] . Such epitopes can be discovered by indirect approaches that can ascertain protein subunit immunogenicity and protective capability in surrogate animal models [ 29 , 30 ] . Accordingly, there is a need for the design and implementation of an effective vaccination strategy that will elicit suffi ciently high-frequency, antigen-specifi c CD8 + T cells to allow thorough characterization of the response to subunit antigens. Unlike replicative microbial vaccines, heterologous proteins and peptides are poorly immunogenic when administered alone. Therefore, to induce a robust antigen-specifi c CD8 + T cell response without the use of infectious agents or antigenloaded exogenous dendritic cells (DCs) [ 31 -33 ] , it is essential to formulate the antigen with an effective adjuvant [ 34 ] . Successful CD8 + T cell-targeted immunization has been demonstrated for peptide epitopes that are formulated with various toll-like receptor (TLR) ligands [ 31 , 35 ] . High-frequency CD8 + T cells can be induced by peptides formulated with polyinosinic-polycytidylic acid (poly(I:C); TLR3 agonist) and co-stimulatory anti-CD40 antibody [ 36 ] . Peptide immunogenicity can be improved via chemical engineering of peptides and adjuvants with amphiphilic albumin-binding tags [ 37 ] . The immunogenicity of peptides can also be modulated through engineered delivery systems ; these are discussed elsewhere [ 38 , 39 ] and, hence, not reviewed here.
It should be noted that full-length protein antigens are typically more desirable for vaccination studies than peptide epitopes. This is because immunization with proteins allows elicitation of both antibody-and T cell-mediated immune responses [ 28 , 40 -42 ] . In addition, one protein may contain several immune epitopes, which is a desirable feature for human vaccines [ 43 ] . Because MHC class I molecules present cytoplasmic antigens, the priming of naïve CD8 + T cells requires cross-presentation of exogenous antigens by antigen-presenting cells ( APCs ) that have taken up the administered protein. Small subsets of DCs-the tissue-resident, generally non-migratory, CD103
+ as well as splenic CD8 + DCs in mice, or CD1c + and CD141 + DCs in humans-play critical roles in cross-presentation of exogenous antigens (reviewed in Refs. [ 15 , 16 ] ). Antigen cross-presentation requires the activation and licensing of the appropriate DC subsets; CD4 + T cells are the classical helper cells for DC activation and licensing (reviewed in Ref. [ 44 ] ). So also, CD4 + T cell help is essential for the differentiation of effector and memory CD8 + T cells (reviewed in Ref. [ 44 ] ). Because MHC class II molecules-which also present processed peptide antigens generated in vacuolar compartments to control the functions of CD4 + T cells-are highly variable, vaccine design requires the identifi cation of helper epitopes and their inclusion in CD8 + T cell-targeted vaccines. Hence, harnessing a non-polymorphic antigen-presenting molecule and invariant T cells as vaccine targets that can provide help can be a viable option for enhancing CD8 + T cell responses to subunit antigens. CD1d and the restricted semi-invariant natural killer T (NKT) cells have shown signifi cant promise as experimental vaccine targets [ 44 ] ; their biology has been recently reviewed elsewhere [ 45 ] .
Immunogenicity of whole-protein antigens formulated with the NKT cell agonist α-galactosylceramide (αGalCer) as the adjuvant has demonstrated that this formulation stimulates robust antigen-specifi c T cell and antibody responses in mice [ 41 , 46 -48 ] . αGalCer is a synthetic glycolipid that closely resembles the marine sponge Agelas mauritianus -derived agelasphin 9b as well as self and bacterial glycolipid antigens ( see Table 1 and references therein). Upon immunization, professional APCs , such as DCs, macrophages, and B cells , take up the administered protein antigen and αGalCer. Antigens undergo processing to short peptide epitopes that are presented by MHC class I molecules expressed Fig. 1 ; [ 28 , 44 , 45 , 49 , 50 ] ). By virtue of its ability to communicate to virtually all cell types of the immune system, αGalCer has proven to be a potent adjuvant that enhances antibody and CD4 T cell responses to foreign antigens (reviewed in Ref. [ 45 ] ). Recognition of αGalCer rapidly activates NKT cells, which produce cytokine/chemokine messengers, thereby trans-activating DCs and initiating a cross talk between members of the innate and adaptive immune systems. NKT cell licensing of DCs facilitates antigen cross presentation by a less well-understood mechanism(s) [ 42 , 44 , 65 ] . Together, this provides stimulus to naïve antigenspecifi c CD8 + T cell precursors that then proliferate and differentiate into effector and memory CD8 + T cells [ 45 ] Several studies have reported that αGalCer is an effective adjuvant for the elicitation of epitope-specifi c CD8 + T cells against the model protein antigen ovalbumin [ 41 , 51 -53 ] , or for enhancing antigen-specifi c CD8 + T cell responses upon immunization with live viral vaccines [ 49 , 54 ] . We recently demonstrated the potency of αGalCer as a CD8 + T cell adjuvant for in vivo immunogenicity and protection studies which exploited pathogenderived protein antigens ( [ 28 ] and unpublished data). It is noteworthy that the activation of NKT cells by αGalCer results in the production of proinfl ammatory as well as immunoregulatory cytokines and chemokines (reviewed in [ 45 ] ). Since DC activation and licensing as well as CD8 + T cell differentiation require proinfl ammatory cytokines and chemokines, efforts to synthesize and identify αGalCer analogues that elicit proinfl ammatory activity are being sought but are not discussed here ( see Table 1 ; reviewed in Ref. [ 55 ] ). Herein, we describe protocols for the preparation of protein antigens and αGalCer adjuvant, mouse immunization, and assessment of antigen-specifi c CD8 + T cell response, while analysis of antigen-specifi c antibody response and protective immunity is not described.
Experiments that assess immunogenicity require a large quantity of pure protein antigens, which, unlike model antigens, are not typically available commercially. Instead, the desired proteins are produced by recombinant DNA methods in Escherichia coli and then purifi ed to a high degree of purity through engineered tags with the use of affi nity resin. We designed, cloned, and produced nine recombinant VACV-derived protein subunits (rA3L , rD1R 565-844 , rD5R 330-470 , rE2L , rF4L , rJ6R , and rL4R , as well as epitope-engineered subunits L4R/B8R [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] and L4R/A34R ), all of which contain a C-terminal histidinetag to facilitate purifi cation ( Fig. 2 ; [ 28 ] ). Upon immunization of mice, αGalCer-formulated antigens induced robust epitope-specifi c CD8 + T cell and antibody responses that were detectable in blood and in various tissues (Fig. 3a-c ) . Vaccination with adjuvant and microbial antigen induced protective immunity against subsequent microbial challenge (Fig. 4 and unpublished data). Our immunization approach is suitable for elicitation of antigen-specifi c CD8 + T cell and antibody responses to recombinant proteins that are produced as insoluble inclusion bodies (IB). Results that have emerged from the use of approaches described herein demonstrate the effi cacy of the proposed immunization strategy for generating high-frequency antigen-specifi c CD8 + T cells against microbial protein antigens that can be exploited for immunologic and vaccine studies. + T cells . Epitope-specifi c CD8 + T cells were detected using a dual-fl uorochrome labeling approach as described previously [ 28 , 66 ] . Contour plots are gated on live 
Materials
Reagents and equipment described herein can be substituted with equivalent alternatives from other vendors.
1. Fisherbrand™ class A clear glass threaded 6 ml vials with caps (Fisher Scientifi c).
2. αGalCer (Funakoshi, Japan); see Table 1 for structure. To dissolve αGalCer, use 5.6 % sucrose, 0.75 % l -histidine, and 0.5 % Tween 20 in sterile water for injection (WFI) for cell culture with heating at 80 °C until dissolved ( see Note 1 ). Make a 0.2 mg/ml stock solution and store at −20 °C.
The immunization protocol reported herein was validated with the use of vaccinia virus (VACV)-derived recombinant proteins designed and produced in our laboratory [ 28 ] and with the model antigen ovalbumin. The following materials are required to obtain recombinant protein antigens for immunizing mice: 38. Sorvall RC-5B refrigerated centrifuge with SS-34 rotor.
39. DU 530 UV/Vis Spectrophotometer (Beckman).
1. Mice: All mice used for immunization were 6-10-week-old males from the following strains: B6-K 0 D 0 ; B * 07 ; 02 tg (B7 tg ) human leukocyte antigen (HLA) class I transgenic (tg) mice were bred in house. B7 tg mouse is described elsewhere [ 56 ] . C57BL/6 (B6) mice were purchased from Jackson Laboratories (Bar Harbor, ME). All animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) at Vanderbilt University.
2. Anesthesia: 10 mg/ml KETAVED (ketamine HCl injection, USP; Vedco) and 1 mg/ml xylazine HCl Injection (xylazine; Vanderbilt pharmacy) in sterile WFI. Ketamine/xylazine anesthesia should be approved by an IACUC at user institution.
3. Purifi ed recombinant antigen or albumin from chicken egg white (ovalbumin, Ova) at 0.5-2 mg/ml in sterile PBS ( see Note 4 ).
4. Sterile insulin syringes, 1 ml (BD Biosciences).
5. Sterile fi lter pipet tips, 1-200 μl (VWR).
1. SmartBox Auto CO 2 System for rodent euthanasia (Euthanex).
2. Refrigerated Sorvall RT7 centrifuge with RTH-750 rotor and plate adaptors. 17. Gibco ACK lysing buffer (Thermo Fisher).
Immunizations

Lymphocyte Isolation
Dimethyl sulfoxide (DMSO
18. Trypan blue solution, 0.4 % in PBS (Fisher Scientifi c).
1. 10 mM Peptide epitope (purity ≥95 %; Schufer-N, Denmark) dissolved in sterile DMSO.
2. Brefeldin A (Sigma). Prepare stock solution at 10 mg/ml in methanol. 9. BD Perm/wash buffer, 10× solution (BD Biosciences).
BD GolgiStop Protein Transport Inhibitor (BD Biosciences
10. Optional: AccuCheck counting beads (Thermo Fisher).
UltraComp eBeads (eBioscience).
12. Falcon 96 Well Round Bottom Cell Culture Plate (Corning).
13. Fisherbrand Polypropylene Microtiter Tubes, 1.2 ml (Fisher Scientifi c).
14. Refrigerated Sorvall RT7 centrifuge with RTH-750 rotor and plate adaptors.
15. LSR-II fl ow cytometer (BD Biosciences).
16. FlowJo fl ow cytometry software (Tree Star, Inc).
17. Tetramers, antibodies , and viability dyes: See Table 2 .
Tetramer Staining, Intracellular Cytokine Staining (ICCS) , and Flow Cytometry
Methods
Follow institutional biosafety and waste disposal regulations when working with chemicals and biologicals. Experimentation involving mice must comply with the experimenters' IACUC regulations. The procedures described here were approved by IACUC at Vanderbilt University. [ 28 , 83 ] , see also "Production protocols" at http://tetramer.yerkes.emory.edu/ ); all tetramers are labeled with phycoerythrin (PE) and stored as 50 μg/ml stock at +4 °C c Representative vendors from which the reagents were purchased. These reagents are also available from the other vendors as well This section describes the preparation of recombinant protein antigen that was used to immunize mice. The sample protocol described below includes the production, purifi cation , and formulation of a VACV protein produced as a recombinant protein by biosynthesis in Escherichia coli ( E. coli ). This protocol was validated for ten different recombinant proteins, three of which were produced in soluble form, with the remaining seven proteins produced in insoluble form as inclusion bodies (IB). Isolated protein antigens proved to be suitable for in vivo immunogenicity and protection studies. Each investigator should optimize this protocol to ensure optimal yield, purity, and solubility of the protein of interest.
1. Plate bacteria transformed with the desired plasmid on freshly prepared LB agar plate containing 50 μg/ml Km and 1 % glucose; incubate overnight at +37 °C. Follow general rules of aseptic techniques when working with E. coli ; that is, perform these procedures around the blue fl ame of a Bunsen burner.
2. Inoculate single colony into 2 ml of LB broth containing 50 μg/ml Km and 1 % glucose; incubate overnight at +37 °C ( see Note 6 ).
3. Inoculate 250 ml LB broth containing 50 μg/ml Km (no glucose) with 1 ml of bacterial culture prepared as from Subheading 3.1 , step 2 , in 2000 ml Nalgene baffl ed shake fl ask; incubate at +37 °C with vigorous shaking (~150 rpm) to A 600 nm = 0.8-1.0 (this level of growth takes ~4 h).
4. Induce expression of the recombinant gene by adding IPTG to 1 mM and continue incubation for an additional 4 h. Optional: Perform analysis of cellular fractions, i.e., total cell lysate as well as soluble and insoluble fractions, by 10-12 % SDS-PAGE to verify expression and solubility of the recombinant protein.
Pause point: Bacterial culture can be stored overnight at +4 °C, or if the protein is produced as IB, cells can be harvested by centrifugation as in Subheading 3.1 , step 5 , and stored frozen at −80 °C, if necessary, for a long period of time.
5. Pellet cells by centrifugation at 3300 × g for 20 min at +4 °C. Discard the supernatant; carefully resuspend the pellet in 5 ml of cell lysis buffer A; then add 5 ml of the same buffer containing 4 mg/ml lysozyme; transfer to 50 ml polypropylene tube and incubate for 30 min on ice.
6. Sonicate with the 550 Sonic Dismembrator ten times for 10 s on ice using a setting of 5 on the Amplitude Control Knob, which is the highest setting for the micro-tip probe. Follow the manufacturer's instructions for the instrument in use.
7. Transfer the cell lysate into 50 ml Nalgene Oak Ridge HighSpeed PPCO Centrifuge tube, and centrifuge at 7670 × g for 20 min at +4 °C. Harvest the pellet and proceed to step 8 if protein is produced as IB; harvest supernatant and proceed to step 9 if soluble protein is produced.
Preparation of Antigen
α-GalCer Adjuvant: Theory, Practice and Protocols 8. To purify IB, discard supernatant and resuspend the pellet in 10 ml cell lysis buffer A without lysozyme by sonication as in Subheading 3.1 , step 6 , followed by centrifugation as in step 7 . To solubilize protein in the IB, resuspend pellet in 0.5 ml PBS by sonication as in Subheading 3.1 , step 6 fi rst, then add 9.5 ml solubilization/wash buffer D ( see Note 7 ).
9. Filter the supernatant through a 45 μm fi lter into a 15 ml polypropylene tube; add 2 ml Ni-NTA slurry, mix, and incubate with rotation for 2 h at +4 °C ( see Note 8 ).
10. Pellet the resin at 300 × g for 5 min at +4 °C and carefully remove the supernatant ( see Note 8 ). Resuspend resin in 14 ml of the appropriate wash buffer: for native protein purifi cation , use wash buffer B; for solubilized denatured protein, use solubilization/wash buffer D. Centrifuge the solution at 300 × g for 5 min at +4 °C. Repeat this wash step.
11. Re-suspend the resin in 5 ml of the corresponding wash buffer as in Subheading 3.1 , step 10 and transfer to a disposable 5 ml polypropylene column. Wash the column four times with 5 ml wash buffer B (for native protein purifi cation ) or D (for solubilized denatured protein purifi cation ).
12. Elute with 3 ml elution buffer C (for native protein purifi cation ) or elution buffer E (for denatured protein purifi cation ). Sterilize the eluted protein by fi ltration through a Millex 0.22 μm fi lter and store at +4 °C on ice. Use for immunization within the next 2 days.
13. Assess purity of isolated protein using 10-12 % SDS-PAGE. SDS-PAGE analysis has been described elsewhere [ 57 ] and, hence, is not described here. Quantify purifi ed protein; one approach is to use a known amount of BSA protein that is separated by SDS-PAGE on the same gel as the recombinant proteins for quantifi cation by densitometry. An average yield of purifi ed recombinant VACV protein is ~1.5-6 mg, which corresponds to ~0.5-2 mg/ml in the eluted fraction. The most common routes for immunizing a mouse are intraperitoneal (IP), subcutaneous (SQ), intravenous (IV), and intranasal (IN). SQ is commonly used for tracking CD8 + T cell responses in the draining lymph node [ 37 ] . Intramuscular (IM) administration is not generally recommended, as the muscle of the mouse is small. The route of immunization used determines traffi cking properties of antigen-specifi c CD8 + T cells and infl uences the anamnestic immune response at the initial site of pathogen invasion [ 58 ] . Hence, choice of immunization route will depend on the investigator's goal and infection model. Below, we describe protocols for IP and IN immunizations, which have been shown to elicit robust and protective CD8 + T cell responses against lethal VACV infection in mice ( [ 28 ] and unpublished data). IP immunization induces a robust systemic response, resulting in antigen-specifi c CD8 + T cells circulating through the blood and secondary lymphoid organs, such as the spleen. IN immunization, in addition to eliciting a systemic response will stimulate a robust local mucosal immune response within the lungs [ 59 ] . Generating a robust antigen-specifi c CD8 + T cell response generally requires two immunizations-prime and boost. Experimentation involving mice must comply with the investigator's IACUC regulations. response to a mild pinch), gradually release 50 μl of the inoculum into both nostrils at the same time with a micropipette. Adjust the rate of release so as to allow the mouse to inhale the inoculum without forming bubbles. This should cause a rapid increase in the breathing rate. Hold the mouse in an upside down position for another couple of minutes until its breathing gradually returns to normal. Observe mice until recovery from anesthesia ( see Note 17 ).
Boost mice 14 days after primary immunization as follows:
prepare mixture of protein and αGalCer as in step 1 and inoculate mice as in step 2 ( see Notes 18 -20 ).
Note that all experimentation involving mice must comply with the investigator's IACUC regulations. In addition, fl ow cytometry should be performed by trained personnel and in accordance with institutional regulations. Refer elsewhere for detailed overviews of fl ow cytometry acquisition and data analysis [ 60 , 61 ] .
1. Sacrifi ce mouse using SmartBox Auto CO 2 System.
2. For each mouse, prepare two 60 mm Petri dishes and place on ice. For IP-immunized mice, remove the spleen and put on top of a 70 μm cell strainer placed inside the Petri dish. For IN-immunized mice, remove the spleen and lungs and place inside separate Petri dishes, each with a 70 μm cell strainer. Harvest spleen or lungs from non-immunized mice as negative controls. Proceed with step 3 to isolate splenic lymphocytes or step 6 to isolate lung lymphocytes ( see Note 21 ).
3. To each spleen, add 2.5 ml ACK lysis buffer at RT. Using the plunger end of a 5 ml syringe, mash the tissue over the cell strainer to disperse leukocytes. Pass the cell suspension one more time though the cell strainer and transfer into a 15 ml polypropylene centrifuge tube. Incubate for 2 min at RT to lyse red blood cells (RBCs). Add 10 ml cRPMI with dasatinib to dilute ACK lysis buffer.
4. Centrifuge the cell suspension at 300 × g for 5 min at +4 °C. Decant supernatant.
5. Resuspend each splenocyte suspension by gentle pipetting in 5 ml FACS buffer and place on ice. To stain splenocytes with various fl uorochrome-conjugated antibodies , proceed to step 9 ( see Note 22 ).
6. Rinse the harvested lungs with PBS to remove blood. Mince tissue with a scalpel; transfer the minced lung tissue into a 15 ml polypropylene centrifuge tube containing 2 ml cRPMI supplemented with dasatinib and 2 mg/ml collagenase and let digest for 1 h at +37 °C.
Isolation of Lymphocytes and Flow Cytometry
7. Pour the digested lung slices onto a 70 μm cell strainer placed inside a Petri dish. Using the plunger end of a 5 ml syringe, mash the tissue over the cell strainer to disperse leukocytes. 14. Prepare an acquisition template using FACSDiva software containing four fl uorochromes to refl ect the staining panel.
15. Set up compensation by using an unstained control and single stained compensation control samples.
16. Set up an acquisition layout containing the following plots: forward scatter (FSC)-A versus side scatter (SSC)-A. Create a gate for the lymphocyte population, and a FSC-W versus FSC-H followed by SSC-W versus SSC-H gate to discriminate singlet population. Create a histogram to display live/dead cells for propidium iodide with a gate to discriminate propidium iodide-negative live population; FITC ("dump" channel) versus CD8α-Pacifi c Blue to create CD8 + T cell gate; CD8α versus tetramer to create tetramer + gate (Fig. 5 ).
17. Collect 5000-10,000 total CD8α + events and export FCS fi les for the analysis in FlowJo software. to each of three wells of 96-well round-bottom plate. To the fi rst well, add 50 μl of cRPMI containing 50 μM antigenic peptide epitope to 10 μM fi nal. Add 50 μl of cRPMI to the second well; this will serve as a negative control for CD8 + T cell re-stimulation. Add 50 μl of cRPMI containing PMA and ionomycin to a fi nal concentration of 50 ng/ml PMA plus 2 μg/ ml ionomycin to the third well; this will serve as a positive control for CD8 + T cell stimulation.
3. Incubate for 2 h at +37 °C in CO 2 incubator (5 % CO 2 ), then add 50 μl cRPMI containing a combination of vesicular transport inhibitors, such as brefeldin A (10 μg/ml fi nal) and GolgiStop (1:1500); incubate for an additional 4 h, for a total of 6 h. These inhibitors will allow for intracellular accumulation of secreted proteins including cytokines such as IFN-γ at levels that are readily detectable by fl ow cytometry .
4. Spin plate at 828 × g for 2 min at +4 °C. Discard the supernatant, resuspend in 250 μl of PBS, and spin again at 828 × g for 2 min at +4 °C to wash the cells. Discard the supernatant. 2. All urea-containing buffers should be made fresh. At physiological pH, urea produces cyanate that can cause carbamylation of proteins by reacting with amino, carboxyl, and sulfhydryl groups, which may alter their stability and function. 3. Refer to methods described elsewhere [ 57 ] for making protein electrophoresis gel and performing SDS-PAGE.
CD8 T Cell
4. Proteins purifi ed from IBs may contain up to 0.05 % SDS for solubility.
5. Low concentrations of dasatinib were reported to substantially improve CD8 + T cell detection with tetramers by preventing T cell receptor internalization [ 62 ] . Dasatinib is a reversible inhibitor that targets a wide variety of protein kinase C family enzymes [ 63 ] . Hence, we routinely use dasatinib in FACS buffer instead of sodium azide to maintain the TCR at the cell surface and for improved staining and cell viability.
6. Use freshly transformed bacterial colonies grown on plates; or alternatively, plate transformed bacteria from frozen glycerol stock.
7. Prior resuspension of IB in PBS through vigorous sonication facilitates further solubilization of proteins within IB by using urea-containing solubilization/wash buffer D. Centrifuge cells at 7670 × g for 20 min at +4 °C and harvest the supernatant.
8. Save an aliquot of the supernatant for SDS-PAGE analysis.
9. LPS is a TLR4 ligand that could potentiate T cell and antibody responses and, hence, we recommend its removal. Nonetheless, we did not fi nd trace amounts of endotoxin contaminants and other impurities co-purifying with the protein preparations to contribute substantially to the elicitation of a CD8 + T cell response in the presence of αGalCer [ 28 ] . In addition, LPS removal in the past has resulted in dramatic losses of VACV protein. Should it become necessary to remove co-purifying endotoxins, use the recently described endotoxin clearance method by including a non-ionic detergent wash step during metal chelation affi nity purifi cation of the protein antigen [ 64 ] .
10. This step is optional because components of elution buffer C do not affect the performance of the immunization protocol or antigen-specifi c immune responses.
11. Proteins purifi ed under denaturing conditions contain a high concentration of urea, which is incompatible with the immunization protocol. Removal of urea by common laboratory approaches may result in protein aggregation. Stimulation of antigen-specifi c T cell responses in vivo does not require native conformation of protein antigen, but does require the protein to be in a reasonably soluble form. Although soluble urea-free protein can be obtained through in vitro refolding, such a procedure is laborious and requires optimization for each protein. We found that a low SDS concentration (0.01-0.05 %) is compatible with IP immunization protocol. This residual low concentration of SDS can promote protein solubility after the removal of urea by dialysis.
12. Some proteins can be refolded successfully and remain soluble after dialysis.
13. αGalCer solution should be clear; if appears cloudy, re-heat at +80 °C until dissolved. Repeated freeze and thaw does not affect the reagent's performance as long as the solution upon thawing remains clear and has not changed color.
14. Prepare mixture of protein with αGalCer right before immunization; usage of SDS-containing protein for IN immunization has not been validated.
15. For the fi rst experiment, we recommend setting up a control wherein the mouse is inoculated IP with the same formulation but without protein antigen. Leukocytes harvested from this mouse after immunization will serve as a control to determine the background of the tetramer staining assay. An additional control for the performance of the reagents and immunization protocol that can be considered is the inclusion of a C57BL/6 mouse immunized by either the IP or IN route with 1 μg of αGalCer and 50 μg of ovalbumin (Ova) as detailed in the main protocol. Ova-specifi c CD8 + should be readily detected with the readily available H2K b /SIINFEKL tetramer (NIH Tetramer Core, Emory University, Atlanta, USA; http://tetramer.yerkes. emory.edu/ ) in the spleen on day 6-14 after boost.
16. Depending on the weight of the mouse, the amount of anesthesia can vary from 125 to 165 μl.
17. For the fi rst experiment, we recommend setting up a control wherein the mouse is inoculated IN with the same formulation containing PBS and αGalCer but without protein antigen. Lymphocytes harvested from this mouse after immunization will serve as a control to determine the background of the tetramer staining assay.
18. Usually, antigen-specifi c CD8 + T cells can be detected at low frequency on days 8-14 after primary immunization. At least one booster immunization substantially increases their frequency, which is more desirable for immunological and vaccination studies.
19. For the fi rst time, before the mouse is sacrifi ced and leukocytes harvested, it may be necessary to confi rm that immunization has induced antigen-specifi c CD8 + T cells of detectable frequency. This can be accomplished by assessing mouse blood leukocytes. A robust antigen-specifi c CD8 + T cell response should be readily detected systemically the blood on day 6-14 after boost.
20. Although it is not reviewed in the protocol here, protein antigen and αGalCer immunization also induces antigen-specifi c antibody responses that can be assessed in mouse serum (but see Fig. 3C ).
21. Harvested organs can be left on ice while additional mice are being processed or reagents are being prepared for up to 24 h. Longer storage times have not been tested.
22
. Cell suspensions can be left on ice for up to 8 h while additional tissues are being processed. Longer storage times have not been tested.
23.
We found that precise counting of CD8 + T cells in the lungs requires counting beads. Counting beads are added directly to staining solution to account for cell losses, assuming proportional bead and cell losses during washes. When working with counting beads, follow vendor's protocol at https://tools. thermofisher.com/content/sfs/manuals/PCB100_accu-check_beads_man.pdf .
24. The investigator should determine optimal staining conditions, such as concentration of tetramer, incubation temperature, and time; each of these parameters will differentially infl uence experimental outcome.
25. Cryopreservation does not affect staining performance but may affect viability. An expected lymphocyte viability after thawing is 80 % or higher.
26. CD107a is a marker for degranulation activity of immune effector cells including CD8 + T cells . Staining with anti-CD107a antibody is optional and performed during re-stimulation of cells. 27 . Upon in vitro re-stimulation, epitope-specifi c CD8 + T cells markedly down-regulate their T cell receptor from the cell surface and, hence, stain poorly with the complex of peptide/ MHC tetramers.
